Senescence in premalignant tumours
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Oncogene-induced senescence is a cellular response that may be crucial for protection against cancer development, but its investigation has so far been restricted to cultured cells that have been manipulated to overexpress an oncogene. Here we analyse tumours initiated by an endogenous oncogene, ras, and show that senescent cells exist in premalignant tumours but not in malignant ones. Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
From Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor (2008) · cites this paper as [16]
In the citing paper
“In addition to identifying known cell-cycle regulators, these studies identified DCR2 as a common marker of senescence (Collado et al., 2005), later shown to characterize other types of senescence.”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“OIS or senescence induced by loss of a tumor suppressor was verified in vivo in human and murine preneoplastic lesions (Collado et al., 2005; Gorgoulis and Halazonetis, 2010; Kuilman and Peeper, 2009) and primary or treated neoplasias (Haugstetter et al., 2010).”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Collado et al., 2005
In the citing paper
“Studies in various mouse models, supported by correlative evidence from human- derived tissue samples, have underscored the tumour- suppressive role of OIS 81,120-123 .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [122]
In the citing paper
“This type of oncogene-induced senescence (OIS) is frequently observed in premalignant and benign tumour tissues [37 -39] but not in advanced malignant tumours, where cancer cells have already bypassed senescence.”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [38]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Self-citationRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
Self-citationTumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571
Self-citation
Cited by
Items 101–200 of 1,005
Cellular senescence: putting the paradoxes in perspective
Campisi, J. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.005 · Cited by 368
Cardiac glycosides are broad-spectrum senolytics
Guerrero, A., Herranz, N., Sun, B., Wagner, V., Gallage, S., Guiho, R., Wolter, K., Pombo, J., Irvine, E. E., Innes, A. J., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0122-z · Cited by 359
Self-citationAdenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies
Succony, L., Rassl, D., Barker, A., McCaughan, F., & Rintoul, R. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102237 · Cited by 342
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
“In both contexts, upregulation of p16 INK4A is considered to be part of a senescence programme that limits inappropriate proliferation and tumorigenesi”
Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras
Friedlander, S. Y. G., Chu, G. C., Snyder, E. L., Girnius, N., Dibelius, G., Crowley, D., Vasile, E., DePinho, R. A., & Jacks, T. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.027 · Cited by 338
“(2) The models utilize distinct K-ras activating mutations (G12V versus G12D), which might have an effect on the oncogenic potency of K-Ras (Bardeesy and Sharpless, 2006; Collado et al., 2005; Seeburg et al., 1984).”
BackgroundTumor-Suppressor Functions of the TP53 Pathway
Aubrey, B. J., Strasser, A., & Kelly, G. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026062 · Cited by 327
“Senescence is often associated with, and is thought to suppress, premalignant lesions preventing their progression to overt malignancy (Collado et al. 2005; Mooi and Peeper 2006).”
BackgroundDimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle, R. C., Squire, J. A., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn024 · Cited by 351
Ferguson, L. R., Chen, H., Collins, A. R., Connell, M., Damia, G., Dasgupta, S., Malhotra, M., Meeker, A. K., Amedei, A., Amin, A., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.005 · Cited by 336
Cellular senescence and organismal aging
Jeyapalan, J. C., & Sedivy, J. M. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.04.001 · Cited by 346
Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer
Mueller, M., Hermann, P. C., Witthauer, J., Rubio–Viqueira, B., Leicht, S. F., Huber, S., Ellwart, J. W., Mustafa, M., Bartenstein, P., D'Haese, J. G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.053 · Cited by 348
Telomeres: Cancer to Human Aging
Stewart, S. A., & Weinberg, R. A. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104518 · Cited by 334
“…researchers have utilized the conditional K-Ras V12 transgenic mouse to demonstrate that nontumorigenic lung adenomas are senescent, displaying the classic markers of this state, including senescenceassociated β-galactosidase (SA-βgal) and high levels of p16INK4A expression (Collado et al. 2005).”
BackgroundMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors
Jessen, W. J., Miller, S. J., Jousma, E., Wu, J., Rizvi, T. A., Brundage, M. E., Eaves, D., Widemann, B., Kim, M.-O., Dombi, E., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60578 · Cited by 334
“However, in benign tumors, Ras signaling can alternatively be associated with oncogene-induced senescence (15, 16), and evidence supports a role for cellular senescence in NF1 dermal neurofibromas (17).”
Yang, G., Rosen, D. G., Zhang, Z., Bast, R. C., Mills, G. B., Colacino, J. A., Mercado-Uribe, I., & Liu, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605752103 · Cited by 341
Meiners, S., Eickelberg, O., & Königshoff, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186914 · Cited by 340
Ralph, S. J., Rodríguez-Enríquez, S., Neuzil, J., Saavedra, E., & Moreno-Sánchez, R. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.008 · Cited by 331
“In related studies using primary pancreatic acinar cells, VK3 action was compared with the related redox blocked and non-cycling analogue, 1,4-dimethoxy-2-methylnapthalene (DMN), along with another drug, diphenyliodonium chloride (DPI) (Criddle et al., 2006).”
BackgroundInfluentialp53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence
Fujita, K., Mondal, A. M., Horikawa, I., Nguyen, G. H., Kumamoto, K., Sohn, J. J., Bowman, E. D., Mathe, E. A., Schetter, A. J., Pine, S. R., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1928 · Cited by 336
“and oncogene-induced, interleukin-regulated premature senescenc”
Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M., Denat, L., Goodall, J., Luciani, F., Viros, A., et al. (2007) · Genes & Development · doi:10.1101/gad.450107 · Cited by 311
“Increasing evidence has highlighted the role of senescence bypass as a critical event in cancer progression (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Xue et al. 2007).”
BackgroundThe First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
“In 137–139”
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
“We quantitatively determined that many markers of senescence (p21, Dcr2, p16, p15, Dec1, and Pml) (Collado et al., 2005; te Poele et al., 2002) were elevated in many stably arrested MMTV-Wnt1 tumors that were p53 wild-type or heterozygous with retention of the wild-type allele, when compared to…”
InfluentialOncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation
Ogrunc, M., Di Micco, R., Liontos, M., Bombardelli, L., Mione, M., Fumagalli, M., Gorgoulis, V. G., & d'Adda di Fagagna, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.16 · Cited by 328
Healing and Hurting: Molecular Mechanisms, Functions, and Pathologies of Cellular Senescence
Adams, P. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.021 · Cited by 326
A High Glycolytic Flux Supports the Proliferative Potential of Murine Embryonic Stem Cells
Kondoh, H., Lleonart, M. E., Nakashima, Y., Yokode, M., Tanaka, M., Bernard, D., Gil, J., & Beach, D. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.1467 · Cited by 325
Self-citationINK4 proteins, a family of mammalian CDK inhibitors with novel biological functions
Cánepa, E. T., Scassa, M. E., Ceruti, J. M., Marazita, M. C., Carcagno, A. L., Sirkin, P. F., & Ogara, M. F. (2007) · IUBMB Life · doi:10.1080/15216540701488358 · Cited by 312
“Although the stability of senescence presumably contributes to its anti-neoplasic activities, the molecular machinery that drives the cell into a permanent state of proliferative arrest is poorly understood ( 34 ).”
BackgroundCao, L., Xu, X., Bunting, S. F., Liu, J., Wang, R.-H., Cao, L. L., Wu, J. J., Peng, T.-N., Chen, J., Nussenzweig, A., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.06.037 · Cited by 309
“…of senescent and apoptotic cells might contribute to organismal aging, as well as serving as a barrier to tumor formation (Bartkova et al., M 2005, 2006; Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Di Micco et al., 2006; Gorgoulis et al., 2005; Michaloglou et al., 2005).”
BackgroundPRAK Is Essential for ras-Induced Senescence and Tumor Suppression
Sun, P., Yoshizuka, N., New, L., Moser, B. A., Li, Y., Liao, R., Xie, C., Chen, J., Deng, Q., Yamout, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.050 · Cited by 321
Ohtani, N. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00197-8 · Cited by 294
“portant tumor suppression mechanism, and cellular senescence is known to be detected precancerous cells [36].”
BackgroundShort Telomeres Limit Tumor Progression In Vivo by Inducing Senescence
Feldser, D. M., & Greider, C. W. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.026 · Cited by 314
“Recently, cellular senescence induced by oncogene expression has been established as a tumor suppressor mechanismin vivo (Braig et al., 2005;Chen et al., 2005;Collado et al., 2005;Michaloglou et al., 2005).”
Regulation of the p53 response and its relationship to cancer
Meek, D. W. (2015) · Biochemical Journal · doi:10.1042/bj20150517 · Cited by 288
Cellular senescence in development, regeneration and disease
Rhinn, M., Ritschka, B., & Keyes, W. M. (2019) · Development · doi:10.1242/dev.151837 · Cited by 279
“In 2005, a series of studies demonstrated that oncogenic mutations in different contexts activate senescence in vivo, as had been previously shown in cells in culture, and that pre-malignant lesions, including papilloma or adenomas in the skin, lung, pancreas, lymphoma and prostate, form through an accumulation of sen…”
BackgroundPluquet, O., Pourtier, A., & Abbadie, C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00334.2014 · Cited by 305
“Senescent cells were also found in benign tumors (26, 77), in the context in which oncogenes were altered, validating in vivo the concept of OIS.”
BackgroundCoppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor
Scaglioni, P. P., Yung, T. M., Cai, L. F., Erdjument-Bromage, H., Kaufman, A. J., Singh, B., Teruya-Feldstein, J., Tempst, P., & Pandolfi, P. P. (2006) · Cell · doi:10.1016/j.cell.2006.05.041 · Cited by 295
“In addition, Pml / mutants display increased mitotic activity and a marked decrease in the induction of the cellular senescence markers p21 and p16, which are known to be upregulated in murine lung models of Ras-induced tumorigenesis (Figure 7B) (Collado et al., 2005).”
Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation
Gewirtz, D. A., Holt, S. E., & Elmore, L. W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.024 · Cited by 281
miR-22 represses cancer progression by inducing cellular senescence
Xu, D., Takeshita, F., Hino, Y., Fukunaga, S., Kudo, Y., Tamaki, A., Matsunaga, J., Takahashi, R.-U., Takata, T., Shimamoto, A., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201010100 · Cited by 289
“Oncogene-induced senescence was found in premalignant tumors but not in more advanced malignant tumors (Braig et al., 2005; Collado et al., 2005).”
Dalmasso, G., Cougnoux, A., Delmas, J., Darfeuille-Michaud, A., & Bonnet, R. (2014) · Gut Microbes · doi:10.4161/19490976.2014.969989 · Cited by 296
“If SASP promotes tumor growth, then cellular senescence is also perceived as an irreversible or prolonged growth arrested state that induces a definitive or prolonged reproductive “dead”(27,28) that is used by senescence-inducing anticancer drugs.(22,29,30) When xenografts were infected by pksC E.”
BackgroundTargeting senescent cells in translational medicine
Paez‐Ribes, M., González‐Gualda, E., Doherty, G. J., & Muñoz‐Espín, D. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201810234 · Cited by 293
“Some of the identified potential markers, such as DEP1 and B2MG (Althubiti et al, 2014), or DCR2 (Collado et al, 2005), although overexpressed in senescent cells are also present in other cells and damaged tissues.”
BackgroundTherapy-Induced Senescence: An “Old” Friend Becomes the Enemy
Saleh, T., Bloukh, S., Carpenter, V. J., Alwohoush, E., Bakeer, J., Darwish, S., Azab, B., & Gewirtz, D. A. (2020) · Cancers · doi:10.3390/cancers12040822 · Cited by 290
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies
Knudsen, E. S., & Witkiewicz, A. K. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2016.11.006 · Cited by 285
Aging of the cells: Insight into cellular senescence and detection Methods.
Mohamad Kamal, N. S., Safuan, S., Shamsuddin, S., & Foroozandeh, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151108 · Cited by 287
Witkiewicz, A. K., Knudsen, K. E., Dicker, A. P., & Knudsen, E. S. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16776 · Cited by 286
Oncogene-induced senescence and tumour control in complex biological systems
Galluzzi, L., & Vitale, I. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-018-0102-y · Cited by 242
p21 transcription is regulated by differential localization of histone H2A.Z
Gévry, N., Chan, H. M., Laflamme, L., Livingston, D. M., & Gaudreau, L. (2007) · Genes & Development · doi:10.1101/gad.1545707 · Cited by 266
“Recently, oncogeneinduced senescence was shown to occur in various precancerous lesions both in humans and mice (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Michaloglou et al. 2005), further suggesting that senescence acts as a defense mechanism against malignant cell development…”
BackgroundBRAFE600 in benign and malignant human tumours
Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 275
“This is accompanied by the induction of the senescenceassociated protein ARF in a subset of the cells, as well as by a newly discovered senescence marker, DEC-1 (Collado et al., 2005).”
BackgroundResultInfluentialγH2AX as a marker of DNA double strand breaks and genomic instability in human population studies
Valdiglesias, V., Giunta, S., Fenech, M., Neri, M., & Bonassi, S. (2013) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2013.02.001 · Cited by 277
Oncogene-Induced Senescence: Putting the Brakes on Tumor Development
Braig, M., & Schmitt, C. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4006 · Cited by 274
The pathways to tumor suppression via route p38
Han, J., & Sun, P. (2007) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.06.007 · Cited by 267
Impact of cellular senescence signature on ageing research
Sikora, E., Arendt, T., Bennett, M., & Narita, M. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2010.10.002 · Cited by 264
Cellular senescence in vivo: a barrier to tumorigenesis
Prieur, A., & Peeper, D. S. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.01.007 · Cited by 260
Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy
Oubaha, M., Miloudi, K., Dejda, A., Guber, V., Mawambo, G., Germain, M.-A., Bourdel, G., Popovic, N., Rezende, F. A., Kaufman, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9440 · Cited by 259
Oncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
“In vivo Inactivation PTEN (TSG) Downregulates PI3K/Akt/mTOR signaling [28 ] VHL (TSG) Targets HIF for degradation [29] Hsp72 Promotes PI3K/Akt (p53-dependent) and ERK (p53-independent) signaling [51] c-Myc Ras signaling effector — transcription and chromatin remodeling factor [120,121] Rb (TSG) Regulates E2F activity…”
BackgroundCharacterization of novel markers of senescence and their prognostic potential in cancer
Althubiti, M., Lezina, L., Carrera, S., Jukes-Jones, R., Giblett, S. M., Antonov, A., Barlev, N., Saldanha, G. S., Pritchard, C. A., Cain, K., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.489 · Cited by 256
“Among these proteins, DCR2, NOTCH3 and ICAM1 were detected, all of which had been previously reported to be increased in senescence.(10,38,39) This confirmed the suitability of the proteomics protocols used for our screen.”
ResultSuppressing Cancer: The Importance of Being Senescent
Campisi, J. (2005) · Science · doi:10.1126/science.1116801 · Cited by 249
Cellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254
Senescent tumor cells lead the collective invasion in thyroid cancer
Kim, Y. H., Choi, Y. W., Lee, J., Soh, E. Y., Kim, J.-H., & Park, T. J. (2017) · Nature Communications · doi:10.1038/ncomms15208 · Cited by 253
Physiological and pathological consequences of cellular senescence
Burton, D. G. A., & Krizhanovsky, V. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1691-3 · Cited by 253
“Another mouse model using inducible K-ras was used to make premalignant lesions that can develop into malignant tumors in lung and pancreas [49].”
MethodDar, A. A., Majid, S., de Semir, D., Nosrati, M., Bezrookove, V., & Kashani-Sabet, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.227611 · Cited by 244
Hoenicke, L., & Zender, L. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs124 · Cited by 248
“A hallmark of senescent cells is the upregulation of senescence-associated ß-galactosidase activity (4), a marker, which in combination with other markers allows to identify senescent cells in vitro or in vivo (5).”
BackgroundMalaquin, N., Martinez, A., & Rodier, F. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.010 · Cited by 247
“…have identified OIS cells in pre-malignant tumours (e.g. pancreatic tumours, melanocytic nevi), but not in more aggressive malignancies, which has prompted the emergence and validation of the idea of senescence as a barrier for cancer development (Collado et al., 2005; Michaloglou et al., 2005).”
Sedelnikova, O. A., Nakamura, A., Kovalchuk, O., Koturbash, I., Mitchell, S. A., Marino, S. A., Brenner, D. J., & Bonner, W. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4442 · Cited by 235
“Senescence is a tumor suppressor mechanism (49), which, like apoptosis and DNA DSB repair, has been proposed to be a programmed protective response to potentially carcinogenic cellular changes (50).”
BackgroundCellular Senescence: Molecular Mechanisms, In Vivo Significance, and Redox Considerations
Muller, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2104 · Cited by 238
“SAHFs are believed to be involved in intrinsic tumor-suppressor activity, and their presence has been detected by using several in vivo models (41, 75).”
Immune System Dysfunction in the Elderly
FUENTES, E., FUENTES, M., ALARCÓN, M., & PALOMO, I. (2017) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201720160487 · Cited by 229
Granule exocytosis mediates immune surveillance of senescent cells
Sagiv, A., Biran, A., Yon, M., Simon, J., Lowe, S. W., & Krizhanovsky, V (2013) · Oncogene · doi:10.1038/onc.2012.206 · Cited by 240
Cell Senescence: Role in Aging and Age-Related Diseases
Campisi, J., & Robert, L. (2014) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000358899 · Cited by 240
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400
Young, A. P., Schlisio, S., Minamishima, Y. A., Zhang, Q., Li, L., Grisanzio, C., Signoretti, S., & Kaelin, W. G. (2008) · Nature Cell Biology · doi:10.1038/ncb1699 · Cited by 239
Ye, X., Zerlanko, B., Kennedy, A., Banumathy, G., Zhang, R., & Adams, P. D. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.034 · Cited by 228
“…is, perhaps, a source of tissue aging and a known tumor suppression process in vivo (Braig et al., 2005; Campisi, 2005; Chen et al., 2005; Collado et al., 2005; Courtois-Cox et al., 2006; Dimri et al., 1995; Janzen et al., 2006; Krishnamurthy et al., 2006; Michaloglou et al., 2005;…”
BackgroundInfluentialClinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma
Bettington, M., Walker, N., Rosty, C., Brown, I., Clouston, A., McKeone, D., Pearson, S.-A., Leggett, B., & Whitehall, V. (2017) · Gut · doi:10.1136/gutjnl-2015-310456 · Cited by 233
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Wyld, L., Bellantuono, I., Tchkonia, T., Morgan, J., Turner, O., Foss, F., George, J., Danson, S., & Kirkland, J. L. (2020) · Cancers · doi:10.3390/cancers12082134 · Cited by 235
Senescence: a new weapon for cancer therapy
Acosta, J. C., & Gil, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.11.006 · Cited by 223
Self-citationATP-Dependent Lon Protease Controls Tumor Bioenergetics by Reprogramming Mitochondrial Activity
Quirós, P. M., Español, Y., Acín-Pérez, R., Rodríguez, F., Bárcena, C., Watanabe, K., Calvo, E., Loureiro, M., Fernández-García, M. S., Fueyo, A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.018 · Cited by 233
“(E) LONP1 relative expression levels in control, senescence-induced, and senescence-bypassed fibroblasts extracted from the data set GSE2484 (Collado et al., 2005).”
MethodSenescent cells: SASPected drivers of age-related pathologies
Ovadya, Y., & Krizhanovsky, V. (2014) · Biogerontology · doi:10.1007/s10522-014-9529-9 · Cited by 232
Loo, T. M., Miyata, K., Tanaka, Y., & Takahashi, A. (2020) · Cancer Science · doi:10.1111/cas.14266 · Cited by 232
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
“Wild-type p53 is associated with senescence in several tumor models, including murine models of non-small cell lung cancer and prostate cancer.(48,49) For example, in a murine prostate cancer model, prostates in Ptenmice display p53-dependent growth arrest and SA-βgal positivity, whereas prostates in Pten;Trp53 mice a…”
BackgroundKumamoto, K., Spillare, E. A., Fujita, K., Horikawa, I., Yamashita, T., Appella, E., Nagashima, M., Takenoshita, S., Yokota, J., & Harris, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2780 · Cited by 223
Actions of human telomerase beyond telomeres
Cong, Y., & Shay, J. W. (2008) · Cell Research · doi:10.1038/cr.2008.74 · Cited by 229
Suram, A., Kaplunov, J., Patel, P. L., Ruan, H., Cerutti, A., Boccardi, V., Fumagalli, M., Di Micco, R., Mirani, N., Gurung, R. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.132 · Cited by 227
Suda, K., Tomizawa, K., & Mitsudomi, T. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9209-4 · Cited by 222
Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells
Arndt, S., Wacker, E., Li, Y., Shimizu, T., Thomas, H. M., Morfill, G. E., Karrer, S., Zimmermann, J. L., & Bosserhoff, A. (2013) · Experimental Dermatology · doi:10.1111/exd.12127 · Cited by 221
The cellular basis for diverse responses to oxygen
Chandel, N. S., & Budinger, G. R. S. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.10.048 · Cited by 219
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
“Premalignant lung adenomas were shown to be positive for senescence markers (62), and activation of AKT by PTEN loss”
BackgroundCritical Functions of the Lysosome in Cancer Biology
Davidson, S. M., & Vander Heiden, M. G. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103101 · Cited by 206
Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway
Wilhelm, M. T., Rufini, A., Wetzel, M. K., Tsuchihara, K., Inoue, S., Tomasini, R., Itie-Youten, A., Wakeham, A., Arsenian-Henriksson, M., Melino, G., et al. (2010) · Genes & Development · doi:10.1101/gad.1873910 · Cited by 203
“The p53 target gene DcR2 has been identified as a marker for oncogeneinduced senescence and is found expressed in premalignant tumors, but expression is lost upon transition to malignant tumors (Collado et al. 2005; Liu et al. 2005).”
BackgroundKennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
“For example, many benign neoplasms harboring activated oncogenes contain senescent cells (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Courtois-Cox et al., 2006; Michaloglou et al., 2005).”
Kondo, Y., Shen, L., Suzuki, S., Kurokawa, T., Masuko, K., Tanaka, Y., Kato, H., Mizuno, Y., Yokoe, M., Sugauchi, F., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00141.x · Cited by 203
Senescent alveolar macrophages promote early-stage lung tumorigenesis
Prieto, L. I., Sturmlechner, I., Graves, S. I., Zhang, C., Goplen, N. P., Yi, E. S., Sun, J., Li, H., & Baker, D. J. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.006 · Cited by 212
Oncogenicity of the Developmental Transcription Factor Sox9
Matheu, A., Collado, M., Wise, C., Manterola, L., Cekaite, L., Tye, A. J., Canamero, M., Bujanda, L., Schedl, A., Cheah, K. S. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3660 · Cited by 209
“In addition, 288 the expression of Ink4b and DcR2, established markers of senescence (34), was 289 inversely correlated with Sox9 levels (Fig.”
ResultSelf-citationThe journey from melanocytes to melanoma
Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 197
MicroRNAs linking inflamm-aging, cellular senescence and cancer
Olivieri, F., Rippo, M. R., Monsurrò, V., Salvioli, S., Capri, M., Procopio, A. D., & Franceschi, C. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.05.001 · Cited by 205
“Increased numbers f senescent cells were noted in human tissues not only during ormal aging, but also in damaged or wounded tissue (Campisi, 011; Collado et al., 2005; Michaloglou et al., 2005).”
Immunosurveillance of senescent cells: the bright side of the senescence program
Sagiv, A., & Krizhanovsky, V. (2013) · Biogerontology · doi:10.1007/s10522-013-9473-0 · Cited by 208
“Indeed, over the past decade mounting data have shown that cellular senescence prevents tumorigenesis (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Michaloglou et al. 2005), limits short-term tissue damage (Fitzner et al.”
BackgroundInfluentialHow to make a melanoma: what do we know of the primary clonal events?
Bennett, D. C. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2007.00433.x · Cited by 198
“It now seems established that a major barrier to the development of cancers, including melanoma, is cell senescence (Collado et al., 2005; Gray-Schopfer et al., 2006; Michaloglou et al., 2005; Mooi and Peeper, 2006).”
BackgroundCosme‐Blanco, W., Shen, M., Lazar, A. J. F., Pathak, S., Lozano, G., Multani, A. S., & Chang, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7400937 · Cited by 205
Senolytics and senostatics as adjuvant tumour therapy
Short, S., Fielder, E., Miwa, S., & von Zglinicki, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.056 · Cited by 202
“Overexpression of oncogenes in otherwise normal cells triggers oncogene-induced senescence via replicative stress [79,80].”
BackgroundCellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
“Senescence contributes to normal development 10,11 , is a protective response that limits fibrosis 12 and acts as a primary barrier to tumorigenesis and malignant progression 13–16 .”
Self-citationCKIα ablation highlights a critical role for p53 in invasiveness control
Elyada, E., Pribluda, A., Goldstein, R. E., Morgenstern, Y., Brachya, G., Cojocaru, G., Snir-Alkalay, I., Burstain, I., Haffner-Krausz, R., Jung, S., et al. (2011) · Nature · doi:10.1038/nature09673 · Cited by 197
BRD7 is a candidate tumour suppressor gene required for p53 function
Drost, J., Mantovani, F., Tocco, F., Elkon, R., Comel, A., Holstege, H., Kerkhoven, R., Jonkers, J., Voorhoeve, P. M., Agami, R., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2038 · Cited by 199
“OIS provides an important barrier to tumour development in vivo”
BackgroundWang, Q., Diskin, S., Rappaport, E., Attiyeh, E., Mosse, Y., Shue, D., Seiser, E., Jagannathan, J., Shusterman, S., Bansal, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4618 · Cited by 199
A comparative analysis of the cell biology of senescence and aging
Hwang, E. S., Yoon, G., & Kang, H. T. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0034-2 · Cited by 190
Keyes, W. M., Pecoraro, M., Aranda, V., Vernersson-Lindahl, E., Li, W., Vogel, H., Guo, X., Garcia, E. L., Michurina, T. V., Enikolopov, G., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2010.12.009 · Cited by 193
“Topical treatment of mouse skin with DMBA induces Ras mutations, which facilitate development of premalignant papillomas with markers and features of OIS; inactivation of mediators of OIS facilitates senescence bypass and converts preneoplastic lesions tomalignant SCC (Collado et al., 2005).”
Metadata
- Authors
- Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., Beach, D., & Serrano, M.
- Affiliations
- Spanish National Cancer Research Centre (ES)
- Imperial College London (GB)
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Serrano, Manuel
- ORCID
- Venue
- Nature
- Published
- 2005-08-04
- Volume
- 436
- Issue
- 7051
- Pages
- 642-642
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2067117191
- Cited by
- 1,482
- References
- 7
- Citations by year
- 2026: 31 · 2025: 40 · 2024: 59 · 2023: 58 · 2022: 57 · 2021: 74 · 2020: 87 · 2019: 55 · 2018: 53 · 2017: 68 · 2016: 67 · 2015: 73 · 2014: 76 · 2013: 81 · 2012: 81
- FWCI
- 46.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, oncogene-induced senescence, oncogenic Ras, lymphoma, SUV39H1, histone methyltransferase, epigenetic regulation, melanoma, p53, PTEN mutation, prostate cancer, tumor suppression, cancer diagnosis and prognosis
- MeSH terms
- Adenocarcinoma, Alleles, Animals, beta-Galactosidase, Cell Transformation, Neoplastic, Disease Models, Animal, Heterochromatin, Lung Neoplasms, Mice, Transgenic, Precancerous Conditions, Genes, ras, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Cellular Senescence, Disease Progression, Cyclin-Dependent Kinase Inhibitor p16, Oligonucleotide Array Sequence Analysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.